0001104659-26-055661
SEC filingProtagonist achieved profitability on milestone revenue and improved operating leverage, while executing a strategic opt-out from the Takeda profit-share to enhance long-term royalty upside.
Revenue for the first quarter of 2026 was $56.4 million, a 99.0% increase from $28.3 million in the same period last year. The increase was primarily due to a $50.0 million milestone payment from the ICOTYDE collaboration. Operating income improved to a loss of $3.6 million from a loss of $19.3 million, an 81.1% improvement, as the milestone revenue more than offset operating expenses. Net income was $3.8 million, or $0.05 per diluted share, compared to a net loss of $11.7 million, or $(0.19) per share, in the prior year.
Subsequent to quarter-end, the company opted out of the Takeda profit-share arrangement for rusfertide, receiving an upfront payment and potential regulatory milestone, along with enhanced royalties. This transaction strengthens the company's balance sheet and provides long-term royalty upside, though specific financial terms are not included in the financial statements.
Research and development expenses increased due to higher personnel-related costs, including wages, benefits and stock-based compensation, partially offset by a decrease in professional services. The company continues to advance its pipeline, including PN-881 and preclinical obesity candidates, with Takeda targeting a rusfertide launch in the second half of 2026, subject to regulatory approval.